the pharmacokinetics of dacarbazine ( dtic ) and its main metabolite 5-aminoimidazole-4-carboxamide ( aic ) have been studied in eight patients with malignant melanoma or sarcoma receiving 2.65 -- 6.85 mg dtic/kg body weight by intravenous bolus injection or by continuous 0.5 -- 6-h infusions on 5 consecutive days .
C0025202
malignant melanoma
C0010927
dtic